IDP-023 alone or with other antibodies for blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has not improved after at least 3 prior treatments, or non-Hodgkin lymphoma that has not improved after at least 2 prior chemotherapies.
- You must be well enough to be up and about (able to do light work or care for yourself).
- Your doctor must expect you to live at least 12 weeks.
- You cannot have serious heart problems, uncontrolled HIV, hepatitis B or C, active COVID-19, or untreated cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
This study tests CM336, a new type of immunotherapy drug, for patients with multiple myeloma (a blood cancer) that has come back or progressed after their first treatment. The trial aims to see if this drug can help control the disease in patients at high risk of relapse.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.